JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand
- S R Mucha1,
- A Rizzani1,
- A L Gerbes1,
- P Camaj2,
- W E Thasler2,
- C J Bruns2,
- S T Eichhorst1,
- E Gallmeier1,
- F T Kolligs1,
- B Göke1,
- E N De Toni1
- 1University of Munich, University Hospital Grosshadern, Department of Medicine 2, Munich, Germany
- 2University of Munich, University Hospital Grosshadern, Department of Surgery, Munich, Germany
- Dr E N De Toni, University of Munich, University Hospital Grosshadern, Department of Medicine II, Research Lab B 5 E01 308, Marchioninistrasse 15, D-81377 Munich, Germany;
- Revised 2 December 2008
- Accepted 11 December 2008
- Published Online First 23 December 2008
Background: cJun terminal kinase (JNK) is constitutively activated in most hepatocellular carcinomas (HCCs), yet its exact role in carcinogenesis remains controversial. While tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known as a major mediator of acquired immune tumour surveillance, and is currently being tested in clinical trials as a novel cancer therapy, the resistance of many tumours to TRAIL and concerns about its toxicity in vivo represent obstacles to its clinical application. In this study we investigated whether JNK activity in HCC could contribute to the resistance to apoptosis in these tumours.
Methods: The effect of JNK/Jun inhibition on receptor-mediated apoptosis was analysed by pharmacological inhibition or RNA interference in cancer cells and non-tumour cells isolated from human liver or transgenic mice lacking a phosphorylation site for Jun.
Results: JNK inhibition caused cell cycle arrest, enhanced caspase recruitment, and greatly sensitised HCC cells but not normal hepatocytes to TRAIL. TRAIL-induced activation of JNK could be effectively interrupted by administration of the JNK inhibitor SP600125.
Conclusions: Expression and TRAIL-dependent feedback activation of JNK likely represent a mechanism by which cancer cells escape TRAIL-mediated tumour surveillance. JNK inhibition might represent a novel strategy for specifically sensitising HCC cells to TRAIL thus opening promising therapeutic perspectives for safe and effective use of TRAIL in cancer treatment.
Funding: This study was funded by the Deutsche Forschungsgemeinschaft (DFG) grant to the KFO128 to BG, and the Förderprogramm für Forschung und Lehre (FöFoLe) of the Ludwig Maximilian University to EDT.
Competing interests: None.
Ethics approval: Tissue sample collection from human liver resections was performed according to the guidelines of the charitable state-controlled foundation Human Tissue and Cell Research.